Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin

Tiffany Guan(University of California San Francisco Medical Center), Bita Fakhri(University of California, San Francisco), Charalambos Andreadis(University of California, San Francisco), Haifaa Abdulhaq(University of California, San Francisco), Rebecca Young(University of California San Francisco Medical Center), Hanson Mouanoutoua(University of California, San Francisco), Mimi Lo(University of California, San Francisco), Lawrence Kaplan(University of California, San Francisco), Fouad Boulbol(Community Medical Center), Raymond Chu(University of California, San Francisco), Weiyun Z. Ai(City College of San Francisco)
Leukemia & lymphoma/Leukemia and lymphoma
July 25, 2022
10.1080/10428194.2022.2100369
Cited by 5

Related Papers

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487